ClinicalTrials.gg

Program

BMS-986533

A development code.

Its studies are led by Bristol-Myers Squibb.

Furthest: phase 1, since Jun 1, 20261 company-led study, 1 open or runningNext primary completion: Jun 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 1since Jun 1, 2026Jun 1, 2026Jun 1, 2027phase 1 · NCT07629999
  • Named in Bristol-Myers Squibb’s own pipeline as BMS-986533, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2026First study: phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyFirst studyNCT07629999 · 136 planned · United States

Ahead

  1. Jun 1, 2027Primary completion: phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyNCT07629999

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07629999Lecithin Cholesterol Acyltransferase Deficiency · United States1RecruitingJun 1, 2027136

How it is read

Names in the registry

  • “BMS-986533”, 1 entry

Codes read as this program: BMS986533.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.